Este resumen de evidencia no es consejo médico. Es un borrador de búsqueda bibliográfica con fuentes para investigación y escritura académica. Revisa siempre los artículos originales antes de citar o aplicar cualquier hallazgo.
Pregunta de investigación
¿La metformina reduce el riesgo cardiovascular?
Respuesta breve
La literatura devuelta debe revisarse por desenlace cardiovascular, comparador, estado de diabetes y diseño del estudio.
Condiciones de búsqueda y resultados
- Afirmación buscada: La metformina puede reducir el riesgo cardiovascular en personas con diabetes tipo 2.
- Intención de búsqueda: Encontrar artículos biomédicos con fuentes sobre metformina y riesgo cardiovascular.
- Conjunto de resultados: Principales artículos biomédicos con fuentes devueltos por LitSource para esta afirmación.
- Última actualización: 2026-05-04
Artículos principales encontrados
| Artículo | Año | Revista | Fuente | Fragmento de evidencia |
|---|---|---|---|---|
| Antihyperglycemic Effects of Annona cherimola Miller and the Flavonoid Rutin in Combination with Oral Antidiabetic Drugs on Streptozocin-Induced Diabetic Mice. | 2023 | Pharmaceuticals (Basel, Switzerland) | PMID 36678609 | Several studies have reported the effects of metformin on atherosclerotic vascular disease in people with type 2 diabetes; our results agree with the previous results presented for metformin, and in combination with EEA… |
| Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study. | 2024 | Diabetologia | PMID 39271516 | The recent international study 'REducing with Metformin Vascular Adverse Lesions' (REMOVAL) suggests a reduction in cardiovascular risk as a result of metformin use in people with long-standing type 1 diabetes. |
| Current and future therapies for type 1 diabetes. | 2021 | Diabetologia | PMID 33595677 | In the large REducing With MetfOrmin Vascular Adverse Lesions (REMOVAL) trial, however, metformin did not reduce the long-term insulin needs or improve glycaemic control in people with long-standing type 1 diabetes and… |
| Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. | 2019 | Endocrinology, diabetes & metabolism | PMID 30815577 | Taking all of this together raises the possibility that the combination of metformin, pioglitazone and a SGLT-2 inhibitor might be additive, with regard to reducing, cardiovascular risk in people with diabetes at high c… |
| The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | 2021 | Diabetologia | PMID 34590174 | Metformin has been evaluated in numerous small trials in people with type 1 diabetes with hopes that its insulin-sensitising properties would improve glycaemic management and/or reduce cardiovascular risk. |
| Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial. | 2024 | Journal of clinical medicine | PMID 39598003 | Conclusions: The empagliflozin/metformin combination improved glycemic control, reduced weight and insulin requirements, and produced several additional beneficial metabolic effects in overweight people with type 1 diab… |
| Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide. | 2025 | Diabetes therapy : research, treatment and education of diabetes and related disorders | PMID 40377834 | Diabetes treatment guidelines advocate consideration of GLP-1 RAs as second-line therapy for people with T2D uncontrolled on metformin, and as first-line therapy in patients with T2D and atherosclerotic cardiovascular d… |
| Mechanisms of action of metformin with special reference to cardiovascular protection. | 2019 | Diabetes/metabolism research and reviews | PMID 31021474 | One of these, the REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL) study, demonstrated a minor and transient reduction for metformin vs placebo of one measure of carotid atherosclerosis in p… |
Qué parece respaldar la evidencia
Los artículos anteriores fueron devueltos por una búsqueda de LitSource con fuentes para esta afirmación. Trátalos como evidencia candidata: revisa el fragmento resaltado y abre el artículo original antes de citar.
Qué sigue siendo incierto
Este borrador no clasifica la certeza clínica, no reemplaza los métodos de revisión sistemática y no decide si la afirmación debe usarse en atención médica. Revisa diseño del estudio, población, intervención, tamaño del efecto y actualidad antes de usar cualquier cita.
Prueba esta búsqueda en LitSource
Pega la afirmación en LitSource para repetir la búsqueda, revisar fragmentos de evidencia actualizados y exportar citas.